Autosomal-dominant (AD) polycystic kidney disease (PKD) is a leading cause of renal failure in the United States, and currently lacks available treatment options to slow disease progression. Mutations in the gene coding for polycystin-1 (PC1) underlie the majority of cases but the function of PC1 has remained poorly understood. We have previously shown that PC1 regulates the transcriptional activity of signal transducer and activator of transcription-6 (STAT6). Here we show that STAT6 is aberrantly activated in cyst-lining cells in PKD mouse models. Activation of the STAT6 pathway leads to a positive feedback loop involving auto/ paracrine signaling by IL13 and the IL4/13 receptor. The presence of IL13 in cyst fluid and the overexpression of IL4/13 receptor chains suggests a mechanism of sustained STAT6 activation in cysts. Genetic inactivation of STAT6 in a PKD mouse model leads to significant inhibition of proliferation and cyst growth and preservation of renal function. We show that the active metabolite of leflunomide, a drug approved for treatment of arthritis, inhibits STAT6 in renal epithelial cells. Treatment of PKD mice with this drug leads to amelioration of the renal cystic disease similar to genetic STAT6 inactivation. These results suggest STAT6 as a promising drug target for treatment of ADPKD.
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signal transduction | cytokines | preclinical A utosomal-dominant (AD) polycystic kidney disease (PKD) is a common, life-threatening genetic disease and a major cause of renal failure in the United States (1, 2) . Excessive proliferation and fluid secretion drive the growth of thousands of epithelial-lined, fluid-filled cysts in the kidney, which leads to destruction of normal renal parenchyma and decline in kidney function. No treatment is currently available to slow disease progression, and most patients eventually require dialysis or kidney transplantation for survival (3) .
Of ADPKD cases, 85% result from mutations in the PKD1 gene coding for polycystin 1 (PC1) (1), a multipass transmembrane protein of poorly understood function (4) . We have previously shown that PC1 undergoes proteolytic cleavage, which releases its cytoplasmic tail from the membrane followed by nuclear translocation and regulation of the transcriptional activity of signal transducer and activator of transcription-6 (STAT6) (5) and STAT3 (6) . Specifically, we found that the PC1 cytoplasmic tail associates with the transcription factors P100 and STAT6, translocates to the nucleus, and coactivates transcription. We have found increased levels of this cleavage fragment in ADPKD kidneys (6) . Interestingly, in mouse models, both knockout or overexpression of PC1 can lead to cystic disease (7, 8) .
Very little is known about the role of STAT6 in renal epithelial cells, and most studies to date have focused on its role in the immune system. Nevertheless, STAT6 is widely expressed in many tissues, including the kidney (5, 9, 10) . STAT6 is activated by cytokine signaling, specifically IL4 or IL13 (9) . In nonimmune cells, STAT6 is typically activated through the type-II IL4/13 receptor, a heterodimer of the IL4Rα and IL13Rα1 chains (11, 12) . In some cell types, STAT6 is known to positively regulate the expression of the IL4/13 receptor chains and the ligands, which leads to a positive feedback loop and persistent pathway activation (13, 14) .
We now report that STAT6 is activated in renal cysts and is part of a positive feedback loop involving IL13 and its receptor, which suggests that cystic epithelial cells are permanently activated by auto/paracrine stimulation. Genetic inactivation of STAT6 in a PKD mouse model leads to significant inhibition of proliferation and cyst growth, and preservation of renal function. Treatment of PKD mice with a STAT6 inhibitory drug, the active metabolite of leflunomide, inhibits renal cyst growth as effectively as STAT6 knockout. These results suggest that STAT6 is a driving force of renal cyst growth in PKD. Therefore, STAT6 is a promising drug target for PKD treatment, especially because leflunomide is already available as a clinically approved drug.
Results

STAT6
Is Activated in Cyst-Lining Cells. To test whether STAT6 is aberrantly activated in polycystic kidneys, we investigated its level of tyrosine phosphorylation in two PKD mouse models. We recently described a human-orthologous mouse model, Pkd1 cond/cond : Nestin cre , in which mosaic inactivation of the Pkd1 gene leads to a robust renal cystic phenotype that replicates many important aspects of human ADPKD, including aberrant activation of mammalian target of rapamycin (mTOR) and STAT3 (6, 15) . Phosphorylated (PY)-STAT6 is strongly elevated in kidneys from 7-wk-old Pkd1 cond/cond :Nestin cre mice compared with unaffected Pkd1 cond/cond controls (Fig. 1A) . Strong PY-STAT6 signals are seen in cyst-lining epithelial cells (Fig. 1C) . Similar results were observed in a second, independent PKD mouse model in 21-d-old animals ( Fig. 1 B and D) . The rapid-onset PKD phenotype in these bpk mice is because of a mutation in the bicaudal C gene (16) . These results indicate that STAT6 is activated in renal cystic epithelial cells and may be a common feature independent of the genotype.
STAT6 and mTOR Activation by IL13 in the Kidney. STAT6 is expressed in normal kidneys ( Fig. 1 A and B) yet the absence of PY-STAT6 indicates that it is normally kept in an inactive state. To test whether STAT6 can be activated in normal renal tubule epithelial cells by IL4 and IL13, normal adult mice were acutely challenged with these cytokines. One hour after intraperitoneal injection of either IL4 or IL13, strong PY-STAT6 signals are observed by immunoblotting (Fig. 1B) . Immunohistochemistry revealed that STAT6 is indeed activated in renal tubule epithelial cells in addition to interstitial cells (Fig. S1 ). These results indicate that STAT6 can be rapidly activated in normal tubule epithelial cells in response to both IL4 and IL13, indicating that they express IL4/13 receptors and readily activatable STAT6. Tubule cells appear to respond consistently stronger to IL13 than to IL4.
In T cells, activation of the IL4Rα has been shown to increase mTOR activity via IRS/PI3K (17) . Because mTOR activity has been clearly linked to renal cyst growth in PKD (15, 16) , we tested whether IL13 can activate mTOR in the kidney. Acute treatment of wild-type mice with IL13 indeed leads to rapid activation of the mTOR pathway, as evidenced by phosphorylation of the downstream marker S6 (Fig. S2 ).
Auto/Paracrine IL13 Signaling Leads to Persistent STAT6 Activation by a Positive Feedback Loop. Next, the distal tubule/collecting duct cell line Madin Darby canine kidney (MDCK) was used to investigate the mechanism of STAT6 activation in renal epithelial cells. MDCK cells normally express STAT6 but contain no detectable, activated PY-STAT6 (Fig. S3 ). Acute treatment with either IL4 or IL13, however, results in strong PY-STAT6 signals, suggesting that MDCK cells express IL4/13 receptors. Fully confluent, quiescent MDCK cells do not express high surface levels of the IL4Rα or IL13Rα1 chains ( Fig. 2A) . Surface expression of the IL13Rα1 chain-but not the IL4Rα chain-is significantly increased in actively growing, subconfluent MDCK cells. To determine if receptor chains are up-regulated because of positive feedback in renal epithelial cells, subconfluent cultures of MDCK cells were treated with IL4 for 9 h, which resulted in strong increases in the surface expression of both the IL4Rα and IL13Rα1 chains ( Fig. 2A) .
Renal tubule epithelial cells are highly polarized and may be exposed to cytokines either via their basolateral surface facing the interstitium or via their apical surface facing the tubule lumen. We investigated the relative sensitivity of fully polarized MDCK cells cultured on permeable Transwell filters toward IL4/ 13 from the apical and basolateral surface, respectively. Cells were acutely treated with IL4 or IL13 apically or basolaterally and the activation of STAT6 was determined by Western blot (Fig. 2B) . IL4 was capable of activating STAT6, whether applied basolaterally or apically, although the basolateral sensitivity was more pronounced. In contrast, IL13 was only capable of activating STAT6 when applied to the basolateral side indicating that the IL13 receptor exhibits strong basolateral polarity in acutely stimulated cells.
Next, we chronically treated polarized MDCK cells with IL4 for 48 h to achieve increased surface expression of the IL4Rα and IL13Rα1 chains, as shown in Fig. 2A . Following an unstimulated rest period, cells were then acutely restimulated with IL13 or IL4, either apically or basolaterally. As shown in Fig. 2B , chronic activation of the STAT6 pathway causes polarized MDCK cells to now become sensitive to apically applied IL13. This finding suggests that the IL13 receptor has either shifted its localization or increased expression in response to STAT6 activation. There is a small but consistent increase in overall STAT6 activation after IL4 pretreatment, indicating that cells have become more sensitized. Overall, these results indicate that kidney epithelial cells are capable of responding to IL4 or IL13 by phosphorylating STAT6, that they activate a positive feedback loop, and that they are sensitive to these cytokines from both apical and basolateral surfaces.
In addition to the IL4/13 receptor chains, in immune cells, the cytokines IL4 and IL13 themselves are also under positive control by STAT6, which likely contributes to the positive feedback loop by auto/paracrine activation, leading to sustained phenotypic differentiation (18) . To test whether the observed activation of STAT6 in cystic epithelial cells in PKD mouse models also results in cytokine expression, we measured IL13 levels in total kidney lysates from bpk mice or age-matched wild-type controls. High levels of IL13 are present in all polycystic kidneys but undetectable in control kidneys (Fig. 2C) . To investigate the origin of IL13 in polycystic kidneys, IL13 levels were determined in aspirated cysts fluids. Similar high levels of IL13 are present in cyst fluid from both the bpk and Pkd1 cond/cond :Nestin cre mouse models, which suggests that this represents the major pool of IL13 in polycystic kidneys. Furthermore, this suggests that cystlining epithelial cells are the likely source of IL13 and that they must have secreted it apically into the cyst lumen. Taken together, these results suggest that cystic epithelial cells exhibit STAT6 activation that is likely sustained by a positive feedback loop involving auto/paracrine stimulation by IL13 in cyst fluid.
To test the relevance of these findings to human ADPKD, we investigated the expression of the IL4/13 receptor chains in microdissected cysts from ADPKD patients compared with control tissue. Microarray analysis carried out as described previously (19) revealed that the gene expression of the IL4Rα and IL13Rα1 chains is significantly up-regulated in cysts compared with control kidney (Fig. 2D) , which was confirmed by quantitative RT-PCR using an expanded sample set (Fig. S4 ). This result is consistent with a previous gene-expression study in which the IL4Rα and IL13Rα1 chains were reported to be upregulated in kidneys of the cpk polycystic mouse model (20) . We also investigated the expression of the IL13Rα2 receptor, which lacks the intracellular signaling domain and is thought to be decoy receptor and inhibitor of the STAT6 pathway (21) . Strikingly, the IL13Rα2 receptor is expressed in control kidneys but is strongly down-regulated in cysts ( Fig. 2D and Fig. S4 ). If polycystic kidneys in mouse models exhibit increased IL4/13 receptor expression, one would expect heightened sensitivity to acute challenge with IL4/13. Indeed, acute treatment with IL4 or IL13 leads to much stronger STAT6 activation in polycystic kidneys compared with wild-type kidneys (Fig. 2E ). Both cyst epithelial cells and interstitial cells exhibit this response (Fig.  S5 ). Taken together, these results suggest that renal cysts in PKD exhibit an activated STAT6-positive feedback loop involving IL13 and the IL4/13 receptor. The inhibitory IL13Rα2 receptor may play an important role in suppressing STAT6 activity in normal kidneys.
Loss of STAT6 Leads to Decreased Cyst Growth in Vivo. Next, we investigated whether inhibition of STAT6 may affect renal cyst growth. STAT6-null mice have previously been generated and were reported to have defects in T-and B-cell differentiation but no apparent renal developmental abnormalities (22) . We crossed Bpk animals with STAT6-null animals that were both in the BALB/c background. bpk/bpk:STAT6 +/+ , bpk/bpk:STAT6 +/− , and bpk/bpk:STAT6 −/− offspring were obtained at the expected Mendelian ratios. Kidneys of bpk/bpk:STAT6 −/− animals are still grossly enlarged and polycystic compared with wild-type controls (Fig. 3A) . However, the severity of the cystic disease is significantly reduced compared with bpk/bpk:STAT6 +/+ animals, and more normal tubule tissue is apparent. Cyst diameters (Fig. 3B ) and kidney weights (Fig. 3D ) are significantly decreased, and the number of normal tubules is significantly increased in bpk/bpk: STAT6 −/− animals compared with the STAT6 +/+ controls. Blood urea nitrogen (BUN) is strongly reduced in bpk/bpk: STAT6 −/− animals compared with bpk/bpk:STAT6 +/+ animals, indicating that the lack of STAT6 leads to preservation of renal function close to wild-type animals (Fig. 3E) . Bpk/bpk:STAT6 −/− kidneys exhibited a reduction in the number of Ki-67 positive proliferating cells (Fig. S6A) , but no change in apoptotic cells (Fig. S6B) , suggesting that the observed inhibition of cyst growth may be primarily because of a reduction of proliferation. Renal cyst fluid from bpk/bpk:STAT6 −/− animals lacked IL13 (Fig. 2C) , confirming that IL13 expression and secretion into cyst lumens is dependent on STAT6.
Renal cyst growth has previously been linked to activation of signaling pathways involving mTOR (16), extracellular signalrelated kinase (ERK) (23) , and STAT3 (6) . Analysis of these signaling proteins using phospho-specific antibodies revealed that the lack of STAT6 does not significantly alter ERK or STAT3 activation in bpk kidneys (Fig. S6C) . However, mTOR activity (as assessed by the level of P-S6) is moderately but consistently down-regulated in bpk/bpk:STAT6 −/− animals compared with bpk/bpk:STAT6 +/+ animals.
Teriflunomide Treatment Alleviates the Cystic Phenotype in Vivo.
These results suggested that STAT6 may be a promising drug target for the treatment of PKD. To further test this theory, we made use of the clinically approved drug leflunomide, which is used for treatment of rheumatoid arthritis. Teriflunomide, the active metabolite of leflunomide, affects several molecular targets, including dihydroorotate dehydrogenase, a key enzyme in the pyrimidine synthesis pathway, which is thought to be the mechanism underlying its efficacy in rheumatoid arthritis (24, 25) . Teriflunomide also acts as a tyrosine kinase inhibitor and has been shown to inhibit STAT6 (26-28). As shown in Fig. 4A , teriflunomide inhibits the IL4-induced activation of STAT6 in MDCK cells in a dose-dependent manner. Treatment of bpk mice from postnatal days 7 to 21 with 1.4 mg/kg teriflunomide every 2 d, a clinically relevant dose, results in a very similar-or even stronger-suppression of renal cyst growth compared with genetic inactivation of the STAT6 gene (Fig. 4B ). Kidney weight (Fig. 4C ) and cystic index (Fig. 4D ) are significantly reduced in treated animals. Renal function is largely preserved as assessed by BUN (Fig. 4E) . The strong PY-STAT6 signal seen in untreated cyst-lining epithelial cells is blunted following teriflunomide treatment, indicating that teriflunomide treatment indeed leads to STAT6 inhibition in the kidney (Fig. S7A) . Teriflunomide treatment does not significantly alter ERK or STAT3 activation in bpk kidneys; however, it moderately but consistently down-regulated P-S6 (Fig. S7B) . We cannot exclude the possibility that other molecular targets of teriflunomide may also play a role, especially as its beneficial effect appeared to exceed that of genetic STAT6 inactivation. We observed a significant degree of toxicity of this compound in young mice, which is likely attributable to the inhibition of pyrimidine synthesis that would be expected to affect growing animals much more severely than adult animals. Future work using more specific STAT6 inhibitors appears warranted to investigate whether toxicity can be reduced or eliminated yet maintain efficacy with regard to the suppression of renal cyst growth. The observed degree of efficacy of teriflunomide treatment is in the same range as that of the mTOR inhibitor rapamycin that we previously used in the same mouse model (16) .
Discussion
We have shown here that the STAT6 pathway is activated in PKD, which leads to a positive feedback loop and likely chronic auto/paracrine stimulation of cyst-lining cells via IL13 and the IL4/13 receptor. First, we have shown that renal epithelial cells in wild-type kidneys are capable of responding to acute IL13 stimulation and that STAT6 is strongly activated in two PKD mouse models (Fig. 1) . Second, we have shown that MDCK cells are capable of responding to IL4/13 signaling by up-regulating their receptor chains and that these chains are up-regulated in PKD, allowing a hyperactivation of PY-STAT6 in cystic animals acutely treated with IL4/13 (Fig. 2) . Finally, we have shown that STAT6 activity is at least a partial driving force of renal cyst growth because genetic STAT6 inactivation ameliorates the cystic disease (Fig. 3) . Because activation of the IL4/13 receptor also leads to mTOR activation in the kidney (Fig S2) , it is possible that this mechanism could partially explain the observed aberrant activity of mTOR in ADPKD and numerous mouse models (15, 16, 29) . STAT6 plays a critical role in the adaptive immune response; it is necessary for the differentiation of T and B cells (22) . In addition, IL13 and STAT6 play an important role in several human diseases, including allergic asthma, where IL13 is responsible for major characteristics of the disease, such as airway hyperresponsiveness, goblet cell hyperplasia, mucus secretion, smooth muscle hyperplasia, and subepithelial fibrosis (30) . IL13 also plays a critical role in tissue fibrosis in the liver and lung (31) , and in inflammatory bowel disease (32) .
The role of STAT6 in the kidney is much less well understood. Because STAT6-null mice have no reported defects in renal development (22) it is unlikely that STAT6 has a critical developmental function in the kidney. We report that STAT6 is abundantly expressed in the mature kidney epithelium but does not appear to be significantly activated in normal animals (Fig.  1 ). Acute treatment with IL4 or IL13, however, leads to rapid STAT6 activation in normal kidneys (Fig. 2E) , suggesting that it is part of a dormant pathway that can rapidly respond to a stimulus. Interestingly, overexpression of human IL13 in a rat model of renal ischemia/reperfusion injury protects from injury (33) . In addition, STAT6 knock-out mice have been reported to sustain increased injury and exhibit delayed repair after renal ischemia/reperfusion injury (34) . Based on these findings, we propose that the IL13/STAT6 signaling pathway plays a role in regulating tubule epithelial repair responses after renal insults. Many of the same signaling pathways and cellular processes are activated in ADPKD and in response to renal injury. This group includes pathways such as mTOR, STAT6, and STAT3, and processes such as tubule cell proliferation, fibrosis, and deposition of extracellular matrix, and has led us to suggest that cyst growth in ADPKD represents the aberrant activation of innate renal repair programs (35) . In addition, it has become clear that genetic defects in the PKD genes per se are insufficient to trigger renal cyst growth but that an additional "third hit" is required (36) . Renal injury can provide such a third hit (37) (38) (39) (40) , presumably because of mitogenic signals by growth factors and cytokines (36) . It is possible that the IL13/STAT6 pathway may be part of a third-hit trigger and may accelerate renal cyst growth in ADPKD patients in response to subclinical levels of renal injury.
Our results suggest that pharmacological inhibition of STAT6 may be a promising avenue for possible therapy of ADPKD. This theory is especially exciting because leflunomide is already an approved drug. Caution is warranted because leflunomide affects several molecular pathways and is a potent drug with significant side effects. Compounds that more specifically affect the STAT6 pathway (41) may prove to be superior and future research is needed to evaluate their efficacy versus side effects. teriflunomide treatment, wt/bpk mice were bred to generate bpk/bpk animals. Pups were genotyped at postnatal day 4 and treated by intraperitoneal injection with vehicle (DMSO in 0.9% sterile saline) or 1. Table  S1 for a list of primers used for quantitative RT-PCR.
Morphometric Analysis. H&E-stained kidney sections were used for quantitative analysis of tubule density, cyst diameter, and cystic index. Detailed descriptions provided in SI Materials and Methods.
BUN. Blood was collected before killing and separated using heparinized plasma collection tubes, then flash-frozen and stored at −80°C. BUN was analyzed using the QuantiChrome Urea Assay Kit (BioAssay Systems).
Statistical Analysis. Data are expressed as means ± SEM. Statistical analyses of one-way ANOVA with Tukey's Multiple Comparison posttests were performed using GraphPad Prism 4.0 (GraphPad Software). 
